Denali Therapeutics
DNLI
128 hedge funds and large institutions have $1.41B invested in Denali Therapeutics in 2020 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 54 increasing their positions, 20 reducing their positions, and 13 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 20
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 108 → 128 (+20)
14% more capital invested
Capital invested by funds: $1.23B → $1.41B (+$175M)
2.53% more ownership
Funds ownership: 73.79% → 76.32% (+2.5%)
24% less call options, than puts
Call options by funds: $367K | Put options by funds: $483K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$68M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$32.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.1M |
| 4 |
PA
Perceptive Advisors
New York
|
+$17.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$81.2M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$6.56M |
| 3 |
Morgan Stanley
New York
|
-$1.95M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$943K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$792K |
DNLI Hedge Fund Activity: Q1 2020 in Review
128 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2020, worth a combined $1.41B — up 14% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new DNLI positions and 13 closed out — a net gain of 22 holders — while 54 added to existing stakes and 20 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, opening a new position worth an estimated $68M. The largest seller was Crestline Management, cutting an estimated $81.2M.
- 128 institutional investors held Denali Therapeutics (DNLI) as of Q1 2020, up from 108 in Q4 2019.
- Funds reported $1.41B of Denali Therapeutics stock for Q1 2020, up 14% quarter-over-quarter.
- 35 funds opened new Denali Therapeutics positions in Q1 2020 and 13 closed out, a net change of +22 holders.
- The largest Denali Therapeutics buyer in Q1 2020 was Gilder Gagnon Howe & Co, an estimated $68M added.
- The largest Denali Therapeutics seller in Q1 2020 was Crestline Management, an estimated $81.2M sold.
Based on aggregated 13F filings for Q1 2020.